Whitehawk Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +13.6% | -2.0% | -4.1% | +0.0% | +21.3% | -71.9% | -68.8% | -80.0% | +0.0% | +0.0% | – | |
| – | +2.0% | +15.4% | -20.9% | -9.9% | -27.5% | -9.4% | +83.7% | -12.0% | -12.1% | -8.2% | -30.7% | – | |
| – | -12,275.0% | – | -84.5% | +82.1% | +46.7% | -12.0% | -570.3% | – | +2,310.3% | -63.4% | -41.9% | – | |
| – | -25.7% | -9.4% | -26.8% | -65.2% | -1.1% | +196.2% | -99.8% | -100.0% | – | – | – | – | |
| – | -71.2% | +189.3% | -133.8% | – | +158.3% | +779.4% | -125.0% | +217.9% | – | +15.3% | -186.8% | – | |
| – | – | -112.5% | – | -100.0% | – | +179,524.5% | -100.9% | -100.0% | – | -100.0% | – | – | |
| – | -1,022.8% | – | – | – | – | – | -141.6% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.